gp-100 peptide vaccine
Vaccineexperimental
Melanocyte protein PMEL also known as premelanosome protein (PMEL), silver locus protein homolog (SILV) or Glycoprotein 100 (gp100), is a protein that in humans is encoded by the PMEL gene. Its gene product may be referred to as PMEL, silver, ME20, gp100 or Pmel17. — Wikipedia
Clinical trial activity
58 trials · 26 clinical orgs · 0 marketing orgs
Phase 1
19
Phase 2
41
Phase 3
2
Phase 4
0
Earliest trial started Jun 1, 1995 (NCT00001439)
Timeline
Indications
Mechanism of action
- Melanocyte protein PMELImmunity, active
PMEL immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPMEL (gene) ↗
- WikipediaGlycoprotein 100 ↗
Also known as
- alvac gp100 vaccine
- anti-gp100:154-162 tcell receptor peripheral blood lymphocyte
- glycoprotein 100
- gp100
- gp100:154-162
- gp100: 209-217
- gp100:209-217
- gp100:280-288
- gp-100 peptide vaccine
- human gp100 plasmid dna vaccine
- mouse gp100 plasmid dna vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01176461 | Phase 1 | Aug 1, 2010 | Bristol-Myers Squibb, Medarex, National Cancer Institute (NCI), University of South Florida |
| NCT01176474 | Phase 1 | Jul 28, 2010 | Bristol-Myers Squibb, Medarex, National Cancer Institute (NCI), University of South Florida |
| NCT00960752 | Phase 2 | May 1, 2010 | University of Texas at Houston |
| NCT00861406 | Phase 1 | Mar 10, 2009 | Merck, University of Texas at Houston |
| NCT00923195 | Phase 2 | Dec 1, 2008 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00610311 | Phase 2 | Jan 1, 2008 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00470015 | Phase 1 | Mar 1, 2007 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT00398073 | Phase 1 | Oct 1, 2006 | Cornell University, National Cancer Institute (NCI) |
| NCT00357461 | Phase 2 | May 1, 2006 | Bristol-Myers Squibb, National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00273910 | Phase 2 | Jan 1, 2006 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00295958 | Phase 2 | Dec 1, 2005 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00303836 | Phase 2 | Nov 1, 2005 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00254397 | Phase 2 | Nov 1, 2005 | University of Texas at Houston |
| NCT00104845 | Phase 1 | Sep 1, 2004 | Cornell University, National Cancer Institute (NCI) |
| NCT00091338 | Phase 1 | Aug 1, 2004 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00091143 | Phase 1 | Jul 1, 2004 | National Cancer Institute (NCI), Providence Health & Services |
| NCT00089063 | Phase 2 | Jun 1, 2004 | National Cancer Institute (NCI), University of Southern California |
| NCT00085189 | Phase 2 | May 1, 2004 | National Cancer Institute (NCI), University of Southern California |
| NCT00077532 | Phase 2 | Mar 1, 2004 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00085397 | Phase 2 | Mar 1, 2004 | Harvard University, National Cancer Institute (NCI) |
Showing 20 of 58 trials
Page 1 / 3
Organizations
Research & Development (26)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 53 | 28 | 4 | 1995 |
| National Institutes of Health (NIH) | Government | 18 | 2 | 2 | 1996 |
| University of Southern California | Academic/Hospital | 9 | 8 | 2 | 1998 |
| Bristol-Myers Squibb | For profit | 3 | 1 | 2 | 2006 |
| Cornell University | Academic/Hospital | 3 | 3 | 2 | 1998 |
| Providence Health & Services | Academic/Hospital | 3 | 1 | 2 | 1999 |
| University of Texas at Houston | Academic/Hospital | 3 | 3 | 2 | 2005 |
| Mayo Clinic | Academic/Hospital | 2 | 1 | 2 | 2000 |
| Medarex | For profit | 2 | 0 | 1 | 2010 |
| University of South Florida | Academic/Hospital | 2 | 2 | 1 | 2010 |
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 1999 |
| Cancer and Leukemia Group B (CALGB) | Academic/Hospital | 1 | 0 | 1 | 2001 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 1997 |
| Eastern Cooperative Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2000 |
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 1 | 1 | 1 | 2002 |
| Genzyme | For profit | 1 | 1 | 1 | 2000 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2004 |
| Indiana University | Academic/Hospital | 1 | 0 | 1 | 1999 |
| Merck | For profit | 1 | 0 | 1 | 2009 |
| Université catholique de Louvain | Academic/Hospital | 1 | 0 | 1 | 2002 |
26 organizations
Page 1 / 2